Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report
Adjuvant lenvatinib in combination with transarterial chemoembolization (TACE) has demonstrated prolonged disease-free survival in hepatocellular carcinoma patients at high risk of recurrence post-resection. Here, we present the case of a 68-year-old woman who developed serious side effects includin...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1505596/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849393157262802944 |
|---|---|
| author | Xiaoqing Li Suhua Ma Qing She Zirong Liu Yanan Liu Yanjing Kuang Xiaozhun Huang Zhengyin Zhan |
| author_facet | Xiaoqing Li Suhua Ma Qing She Zirong Liu Yanan Liu Yanjing Kuang Xiaozhun Huang Zhengyin Zhan |
| author_sort | Xiaoqing Li |
| collection | DOAJ |
| description | Adjuvant lenvatinib in combination with transarterial chemoembolization (TACE) has demonstrated prolonged disease-free survival in hepatocellular carcinoma patients at high risk of recurrence post-resection. Here, we present the case of a 68-year-old woman who developed serious side effects including pemphigus erythematosus (PE) linked to lenvatinib usage. Initially treated for breast cancer with radical surgery in April 2018 followed by adjuvant therapy, she was later diagnosed with liver cancer, initially mistaken for metastatic breast cancer to the liver. Although systemic treatment for advanced breast cancer was received, the tumor continued to progress and required partial removal of the liver after final evaluation. Subsequent pathology revealed hepatocellular carcinoma combined with risk factors for recurrence, prompting adjuvant therapy with TACE and oral lenvatinib. After three weeks of lenvatinib administration, the patient developed a skin rash diagnosed as PE through skin pathology. Treatment involved oral methylprednisolone, intravenous human immune globulin, and supportive care, resulting in a cure within a month. This unique case highlights the importance of further research not only on lenvatinib but also on monitoring and managing adverse reactions associated with targeted drugs to optimize patient safety and treatment outcomes. |
| format | Article |
| id | doaj-art-8aca02a653f6463d9a48067c39aa8b7e |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-8aca02a653f6463d9a48067c39aa8b7e2025-08-20T03:40:33ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-03-011510.3389/fonc.2025.15055961505596Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case reportXiaoqing LiSuhua MaQing SheZirong LiuYanan LiuYanjing KuangXiaozhun HuangZhengyin ZhanAdjuvant lenvatinib in combination with transarterial chemoembolization (TACE) has demonstrated prolonged disease-free survival in hepatocellular carcinoma patients at high risk of recurrence post-resection. Here, we present the case of a 68-year-old woman who developed serious side effects including pemphigus erythematosus (PE) linked to lenvatinib usage. Initially treated for breast cancer with radical surgery in April 2018 followed by adjuvant therapy, she was later diagnosed with liver cancer, initially mistaken for metastatic breast cancer to the liver. Although systemic treatment for advanced breast cancer was received, the tumor continued to progress and required partial removal of the liver after final evaluation. Subsequent pathology revealed hepatocellular carcinoma combined with risk factors for recurrence, prompting adjuvant therapy with TACE and oral lenvatinib. After three weeks of lenvatinib administration, the patient developed a skin rash diagnosed as PE through skin pathology. Treatment involved oral methylprednisolone, intravenous human immune globulin, and supportive care, resulting in a cure within a month. This unique case highlights the importance of further research not only on lenvatinib but also on monitoring and managing adverse reactions associated with targeted drugs to optimize patient safety and treatment outcomes.https://www.frontiersin.org/articles/10.3389/fonc.2025.1505596/fulllenvatinibhepatocellular carcinomapemphigusadverse drug reactioncase report |
| spellingShingle | Xiaoqing Li Suhua Ma Qing She Zirong Liu Yanan Liu Yanjing Kuang Xiaozhun Huang Zhengyin Zhan Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report Frontiers in Oncology lenvatinib hepatocellular carcinoma pemphigus adverse drug reaction case report |
| title | Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report |
| title_full | Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report |
| title_fullStr | Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report |
| title_full_unstemmed | Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report |
| title_short | Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report |
| title_sort | lenvatinib induced pemphigus erythematosus in hepatocellular carcinoma a unique case report |
| topic | lenvatinib hepatocellular carcinoma pemphigus adverse drug reaction case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1505596/full |
| work_keys_str_mv | AT xiaoqingli lenvatinibinducedpemphiguserythematosusinhepatocellularcarcinomaauniquecasereport AT suhuama lenvatinibinducedpemphiguserythematosusinhepatocellularcarcinomaauniquecasereport AT qingshe lenvatinibinducedpemphiguserythematosusinhepatocellularcarcinomaauniquecasereport AT zirongliu lenvatinibinducedpemphiguserythematosusinhepatocellularcarcinomaauniquecasereport AT yananliu lenvatinibinducedpemphiguserythematosusinhepatocellularcarcinomaauniquecasereport AT yanjingkuang lenvatinibinducedpemphiguserythematosusinhepatocellularcarcinomaauniquecasereport AT xiaozhunhuang lenvatinibinducedpemphiguserythematosusinhepatocellularcarcinomaauniquecasereport AT zhengyinzhan lenvatinibinducedpemphiguserythematosusinhepatocellularcarcinomaauniquecasereport |